Biohaven Ltd. (BHVN)

NYSE • Healthcare

$12.87

-$0.27 (-2.1%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$13.41

Day Range$12.63 - $13.51

Avg. Volume (3M)3M

Market Cap$1.9B

52 Week Range

$7.48$18.57

Next EarningsIn 36 daysNov 9, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$586.8M

EPS (TTM)

-$4.64

ROA (TTM)

-158.29%

Current Ratio

4.73

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

0.0%Q3 2025-$1.94

+14.1%Q4 2025-$1.64

+0.8%Q1 2026-$1.21

-2.3%Q2 2026-$0.88

-19.6%Q3 2026-$0.91

Nov 9

in 36 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -19.6%

Biohaven Ltd. missed on EPS in the second fiscal quarter of 2026, with preliminary results reported on 2026-08-10 showing EPS of -$0.91 versus the -$0.76 estimate, a -19.6% miss. Gross profit was $0, operating income was negative about $124.9 million, and operating cash flow was negative $85.1 million. Net income came in at negative about $137.3 million, up 30.7% from negative $198.1 million a year ago, while EPS was up 53.1% from -$1.94.

View full earnings history

About Biohaven Ltd.

Biohaven Ltd. is a clinical-stage Biotechnology company listed on the NYSE under BHVN. The company develops drug candidates for disorders affecting the nervous and immune systems, placing it in the healthcare sector, and it remains in the trial stage rather than operating as a mature commercial pharmaceutical business.

Name

Biohaven Ltd.

CEO

Vladimir Coric

Website

www.biohaven.com

Industry

Healthcare

Employees

274

Today's Snapshot

AI-generated

BHVN closed 2% below yesterday's close, while its sector was flat. Volume was about two-thirds of its usual level. Biohaven’s pivotal epilepsy trial was placed on clinical hold.

Trading Volume

Below 10d avg (2.1M)

1.4M

vs S&P 500 Today

Underperforming Market

-2.80%

Updated: October 2, 2026 at 20:10 UTC

Technical Indicators

1 Buy2 Neutral5 Sell

BHVN shows a defensive technical profile with the price trading below short- and medium-term moving averages while remaining modestly above the 200-day averages, suggesting longer-term support but short-term pressure. Momentum indicators are tilted negative, with MACD and a recent momentum reading on the soft side, while RSI and other oscillators sit in neutral territory, implying limited buying conviction. Trend strength is weak, as ADX is low, and volatility is elevated relative to price, reflected in a larger ATR. On-balance volume tilts negative, underscoring distribution. Technical takeaway: Sell.

All signals